Bone Metastasis Companies

Latest Bone Metastasis Companies Updates:

Amgen Received FDA approval for EVENITY™ (romosozumab-hxc) Injection, a new bone-sparing agent offering dual mechanism of action for reducing the risk of skeletal-related events (SREs) in adults with advanced solid tumors and bone metastases.

Eli Lilly and Company Initiated Phase 3 clinical trial evaluating the efficacy and safety of Verzenio™ (abemaciclib) in combination with Xeloda™ (capecitabine) for treating patients with first-line metastatic or locally advanced gastric cancer with bone metastases.

AstraZeneca Expanded the label for Zoladex® (goserelin acetate) implant for prostate cancer, now including an indication for reducing the risk of SREs in men with hormone-naive metastatic prostate cancer.

Novartis Acquired Genmab A/S, gaining access to promising late-stage bispecific antibody drugs with potential applications in treating various cancers, including those with bone metastases.

Merck & Co., Inc. Partnered with University of California, San Francisco to develop and commercialize novel targeted therapies for bone metastases arising from specific cancer types.Roche Diagnostics: Collaborated with medical technology companies to develop AI-powered solutions for analyzing imaging data and predicting the risk of bone metastases in cancer patients.

List of Bone Metastasis Key companies in the market:

• F. Hoffmann-La Roche Ltd (Switzerland)


• Bayer AG (Germany)


• Merck & Co., Inc. (U.S.)


• Pfizer Inc. (U.S.)


• Novartis AG (Switzerland)


• Pharmalucence Inc. (England)


• Koninklijke Philips N.V. (the Netherlands)


• GENERAL ELECTRIC (U.S.)


• Siemens AG (Germany)